1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 21, 27/May/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January–April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.21.2100438
2021-05-27
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.21.2100438
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/21/eurosurv-26-21-2.html?itemId=/content/10.2807/1560-7917.ES.2021.26.21.2100438&mimeType=html&fmt=ahah

References

  1. European Center for Disease Control and Prevention (ECDC). Case definition for coronavirus disease 2019 (COVID-19, as of 3 December 2020. Stockholm: ECDC. [Accessed: 26 May 2021]. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
  2. Ministerio de Sanidad. Estrategia de detección precoz, vigilancia y control de COVID-19. Actualizado a 26 de febrero de 2021. [Strategy for early detection, surveillance and control of COVID-19. Updated 26 February 2021]. Madrid: Spanish Ministry of Health. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
  3. European Centre for Disease Prevention and Control (ECDC). Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union –third update, 18 November2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-contact-tracing-public-health-management-third-update.pdf
  4. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MA, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27(3):472.e7-10.  https://doi.org/10.1016/j.cmi.2020.11.004  PMID: 33189872 
  5. European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. 19 November 2020. ECDC: Stockholm; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen-tests-for-COVID-19_0.pdf
  6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  7. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91.  https://doi.org/10.1016/S0140-6736(21)00432-3  PMID: 33617777 
  8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. , COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  9. Consejo Interterritorial del Sistema Nacional de Salud. Estrategia de vacunación frente a COVID-19 en España. Actualización 6, 20 abril 2021. [COVID-19 vaccination strategy in Spain. 6th update, 20 April 2021]. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social; 2021. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion6_EstrategiaVacunacion.pdf
  10. World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness. Interim Guidance, 17 March 2021. Geneva: WHO. [Accessed: 5 May 2021]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1
  11. Dwivedi AK, Mallawaarachchi I, Lee S, Tarwater P. Methods for estimating relative risk in studies of common binary outcomes. J Appl Stat. 2014;41(3):484-500.  https://doi.org/10.1080/02664763.2013.840772 
  12. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard. Geneva: WHO. [Accessed: 2 May 2021]. Available from: https://covid19.who.int
  13. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.  https://doi.org/10.15585/mmwr.mm7013e3  PMID: 33793460 
  14. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines against COVID-19 among hospitalized adults aged ≥65 years — United States, January–March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9.  https://doi.org/10.15585/mmwr.mm7018e1  PMID: 33956782 
  15. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-57.  https://doi.org/10.1016/S0140-6736(21)00677-2  PMID: 33901420 
  16. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  17. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  18. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis. 2021;ciab361.  https://doi.org/10.1093/cid/ciab361  PMID: 33900384 
  19. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill. 2021;26(17):2100420.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100420  PMID: 33928898 
  20. Lewnard JA, Patel MM, Jewell NP, Verani JR, Kobayashi M, Tenforde MW, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology. 2021;Publish Ahead of Print.  https://doi.org/10.1097/EDE.0000000000001366  PMID: 34001753 
Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Ana+Miqueleiz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Miqueleiz Ana</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Ana+Navascu%C3%A9s&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Navascués Ana</a>, <a href="/search?value1=Camino+Trobajo-Sanmart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trobajo-Sanmartín Camino</a>, <a href="/search?value1=Cristina+Burgui&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Burgui Cristina</a>, <a href="/search?value1=Marcela+Guevara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guevara Marcela</a>, <a href="/search?value1=Carmen+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Carmen</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Working+Group+for+the+Study+of+COVID-19+in+Navarra&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Working Group for the Study of COVID-19 in Navarra</a></span>. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(21):pii=2100438. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 May 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 27 May 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.21.2100438
/content/10.2807/1560-7917.ES.2021.26.21.2100438
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error